Composition for Treating Virus Infection Disease Comprising Jab1

Abstract

Disclosed is a composition for treating or preventing a viral infection or associated disease comprising a Jab1 protein, a nucleic acid having a nucleotide sequence coding for a Jab1 protein or a recombinant virus expressing a jab1 protein.

1 . A composition for treating or preventing a flavivirus or pestivirus infection, comprising a Jab1 (Jun-activation binding protein 1) protein. 
     
     
         2 . The composition as set forth in  claim 1 , wherein the Jab1 protein has an amino acid sequence designated as SEQ ID No. 2. 
     
     
         3 . The composition as set forth in  claim 1 , wherein the Jab1 protein is encoded by a nucleotide sequence designated as SEQ ID No. 1. 
     
     
         4 . A composition for treating or preventing a flavivirus or pestivirus infection, comprising a nucleic acid having a nucleotide sequence coding for a Jab1 protein. 
     
     
         5 . The composition as set forth in  claim 4 , wherein the nucleic acid having the nucleotide sequence coding for the Jab1 protein is a recombinant vector having a nucleotide sequence coding for an amino acid sequence designated as SEQ ID No. 2. 
     
     
         6 . The composition as set forth in  claim 4 , wherein the nucleic acid having the nucleotide sequence coding for the Jab1 protein is a recombinant vector having a nucleotide sequence designated as SEQ ID No. 1. 
     
     
         7 . The composition as set forth in  claim 5  or  6 , wherein the recombinant vector is a recombinant viral vector. 
     
     
         8 . The composition as set forth in  claim 7 , wherein the recombinant viral vector is selected from among recombinant retrovirus, adenovirus, adeno-associated virus and herpes simplex virus. 
     
     
         9 . A composition for treating or preventing a flavivirus or pestivirus infection, comprising a recombinant virus expressing a Jab1 protein. 
     
     
         10 . The composition as set forth in  claim 9 , wherein the recombinant vector expressing the Jab1 protein is a recombinant virus expressing a Jab1 protein having an amino acid sequence designated as SEQ ID No. 2. 
     
     
         11 . The composition as set forth in  claim 9 , wherein the recombinant vector expressing the Jab1 protein is a recombinant virus expressing a Jab1 protein encoded by a nucleotide sequence designated as SEQ ID No. 1. 
     
     
         12 . The composition as set forth in  claim 9 , wherein the recombinant vector is selected from among adenovirus, adeno-associated virus and herpes simplex virus. 
     
     
         13 . The composition as set forth in  claim 12 , wherein the recombinant vector is selected from among retrovirus and adenovirus. 
     
     
         14 . The composition as set forth in any one of  claims 1 ,  4  and  9 , wherein the infection is a flavivirus infection. 
     
     
         15 . The composition as set forth in  claim 14 , wherein the flavivirus is West Nile virus. 
     
     
         16 . The composition as set forth in any one of  claims 1 ,  4  and  9 , wherein the infection is associated with fever, rash, bleeding, jaundice, arthralgia, myalgia, encephalitis or meningitis. 
     
     
         17 . A method of screening a compound stimulating expression of a Jab1 protein, comprising:
 (a) culturing a cell expressing the Jab1 protein;   (b) contacting the cell cultured at (a) with candidate compounds for stimulating expression of the Jab1 protein;   (c) comparing an expression level of the Jab1 protein at (b) with that in a control not contacted with the candidate compounds; and   (d) identifying a compound increasing expression levels of the Jab1 protein.   
     
     
         18 . A method of screening a compound stimulating interaction between a Jab1 protein and a capsid (Cp) protein, comprising:
 (a) culturing a cell transformed with both a recombinant vector expressing the Jab1 protein and another recombinant vector expressing the Cp protein of flavivirus or pestivirus;   (b) contacting the cell cultured at (a) with candidate compounds for stimulating interaction between the Jab1 protein and the Cp protein;   (c) comparing an expression level of the Cp protein at (b) with that in a control not contacted with the candidate compounds; and   (d) identifying a compound reducing expression levels of the Cp protein.   
     
     
         19 . The method as set forth in  claim 17  or  18 , wherein the comparison of expression levels at (c) is carried out in protein or mRNA levels. 
     
     
         20 . The method as set forth in  claim 19 , wherein the comparison of expression levels is carried out by an immunoassay method. 
     
     
         21 . The method as set forth in  claim 19 , wherein the comparison of expression levels is carried out in mRNA levels by RT-PCT (Reverse Transcription-Polymerization Chain Reaction).